Home › Breast Cancer › Virginia
Breast Cancer clinical trials in Virginia
84 studies for Breast Cancer are looking for participants at sites in Virginia.
Cities in Virginia
- Arlington50 studies
- Richmond27 studies
- Norfolk17 studies
- Charlottesville9 studies
- Alexandria7 studies
- Roanoke7 studies
- Winchester5 studies
- Lynchburg4 studies
- Waynesboro4 studies
- Fredericksburg3 studies
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06797635A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
- Virginia Cancer Institute, Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07827573S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Norfolk
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07905001A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07007559The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- and 5 more
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, PC, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06324357Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Inova, Fairfax
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Next Oncology, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Virginia Cancer Specialists, PC, Fairfax
- Virginia Oncology Associates, Norfolk
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336E-Mindfulness Approaches for Living After Breast Cancer
- Inova Alexandria Hospital, Alexandria
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- and 14 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Virginia Health System, Charlottesville
- Inova Schar Cancer Institute, Fairfax
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Virginia Cancer Specialists, Fairfax
- USOR Virginia Oncology Associates, Norfolk
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- and 6 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Inova Schar Cancer Institute, Falls Church
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472Distance-Based Exercise to Preserve Function and Prevent Disability
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- Bon Secours Saint Francis Medical Center, Midlothian
- Bon Secours Saint Mary's Hospital, Richmond
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Kaiser Permanente-Burke Medical Center, Burke
- University of Virginia Cancer Center, Charlottesville
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- and 12 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
- Shenandoah Oncology ( Site 8004), Winchester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07060807A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- Next Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 3, 2026 · NCT07524855Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07524322ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Bon Secours Cancer Institute at Memorial Regional, Mechanicsville
- Bon Secours St. Francis Medical Center, Midlothian
- Bon Secours Cancer Institute at St. Mary's, Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07173751A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Inova Schar Cancer Institute, Falls Church
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
- Shenandoah Oncology, Winchester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07102381A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- NEXT Oncology, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Alan B. Pearson Regional Cancer Center, Lynchburg
- Bon Secours Cancer Institute at St. Francis, Midlothian
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06401421A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Virginia Oncology Associates (Norfolk) - USOR, Norfolk
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07100106Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345Single FrAction Interstitial BreaSt BracHytherApy
- Virginia Commonwealth University, Richmond
RecruitingPhase 2
Ages 40 to 85 · Women · Updated Oct 23, 2026 · NCT07654257A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07383506A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07287995Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Virginia Cancer Specialists-Fairfax, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07287917Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Inova Schar Cancer Institute ( Site 0051), Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06686394A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Midlothian
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 19, 2026 · NCT07647328A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Virginia Cancer Specialists, PC, Arlington
- Virginia Oncology Associates, Chesapeake
- Virginia Cancer Specialists, Fairfax
- and 8 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors
- NEXT Virginia Cancer Center- Merrifield Tech Center, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07767474From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.